OmniAb, Inc.
Tony Cosentino, CPA has a diverse work experience in the field of accounting. Tony is currently working as the Director of SEC Reporting & Technical Accounting at OmniAb, Inc. starting from June 2022. Prior to this, they worked at Arena Pharmaceuticals, Inc. from November 2020 to June 2022, where they held the positions of Director of Technical Accounting and Financial Reporting, as well as Associate Director of Accounting. At Arena Pharmaceuticals, Tony was responsible for various tasks including SEC reporting, technical accounting, SOX compliance, and internal audit.
Before their tenure at Arena Pharmaceuticals, Tony worked as the SEC Reporting Manager at Encore Capital Group from June 2018 to November 2020. In this role, they oversaw the preparation and review of 10K and 10Q filings, ensuring compliance with SEC and GAAP guidelines. Tony also researched new accounting pronouncements and drafted technical disclosures.
Tony's earlier experience includes working as an Equity Research Analyst at Voyant Advisors LLC from July 2016 to June 2018. Prior to that, they spent four years at EY, first as an Assurance Senior from August 2012 to July 2016, and earlier as an Assurance Intern from June 2011 to August 2011.
Throughout their career, Tony has gained expertise in SEC reporting, technical accounting areas such as contract revenue, lease accounting, equity method accounting, stock compensation, business combinations, consolidation, and foreign currency. Tony has also demonstrated knowledge and experience in SOX compliance and internal audit.
Tony Cosentino, CPA, pursued their education at Point Loma Nazarene University from 2008 to 2012. During this time, they completed a Bachelor of Arts (BA) degree with a double major in Business Administration and Accounting. In February 2014, Tony obtained the Certified Public Accountant (CPA) certification from the Board of Accountancy.
This person is not in the org chart
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.